Distribution of clinical and pathology variables between follicular and diffuse pattern of FOXP3+ cells
| Feature . | No. patients with follicular FOXP3+ cells, (%) . | No. patients with diffuse FOXP3+ cells (%) . | Total (%) . | P . |
|---|---|---|---|---|
| No. | 38 (37) | 64 (63) | 102 (100) | |
| Clinical features | ||||
| Median age (y) | 45 | 45 | .9 | |
| Female (%) | 15 (40) | 37 (58) | .6 | |
| Median follow-up (y) | 17 | 16 | .011 | |
| IPI | ||||
| Group 1 (0/1) | 19 50) | 43 (67) | 62 (61) | .14 |
| Group 2 (2/3) | 19 (50) | 20 (32) | 39 (38) | |
| Group 3 (4/5) | 0 (0) | 1 (1) | 1 (1) | |
| BM involvement | 22 (60) | 29 (45) | 52 (51) | .3 |
| Treatment response | ||||
| CR | 18 (47) | 40 (63) | 58 (57) | .3 |
| PR | 19 50) | 22 (34) | 41 (40) | |
| NR | 1 (3) | 2 (3) | 3 (3) | |
| Pathology features | ||||
| FL Grade | ||||
| Grade 1 | 29 (76) | 51 (80) | 80 (78) | .8 |
| Grade 2 | 6 16) | 10 (16) | 16 (16) | |
| Grade 3 | 3 (8) | 3 (4) | 6 (6) | |
| FOXP3 cells, MD (SD) | 312 (145) | 200 (125) | < .001 | |
| LAM > 15 cells HPF | 11 | 1 | 12 (12) | < .001 |
| CD4/8 pattern (F) | 29 | 40 | 69 (68) | .2 |
| CD25 pattern (F) | 31 | 7 | 38 (37) | < .001 |
| Transformation | 12 (32) | 9 (14) | 20 (20) | .04 |
| Feature . | No. patients with follicular FOXP3+ cells, (%) . | No. patients with diffuse FOXP3+ cells (%) . | Total (%) . | P . |
|---|---|---|---|---|
| No. | 38 (37) | 64 (63) | 102 (100) | |
| Clinical features | ||||
| Median age (y) | 45 | 45 | .9 | |
| Female (%) | 15 (40) | 37 (58) | .6 | |
| Median follow-up (y) | 17 | 16 | .011 | |
| IPI | ||||
| Group 1 (0/1) | 19 50) | 43 (67) | 62 (61) | .14 |
| Group 2 (2/3) | 19 (50) | 20 (32) | 39 (38) | |
| Group 3 (4/5) | 0 (0) | 1 (1) | 1 (1) | |
| BM involvement | 22 (60) | 29 (45) | 52 (51) | .3 |
| Treatment response | ||||
| CR | 18 (47) | 40 (63) | 58 (57) | .3 |
| PR | 19 50) | 22 (34) | 41 (40) | |
| NR | 1 (3) | 2 (3) | 3 (3) | |
| Pathology features | ||||
| FL Grade | ||||
| Grade 1 | 29 (76) | 51 (80) | 80 (78) | .8 |
| Grade 2 | 6 16) | 10 (16) | 16 (16) | |
| Grade 3 | 3 (8) | 3 (4) | 6 (6) | |
| FOXP3 cells, MD (SD) | 312 (145) | 200 (125) | < .001 | |
| LAM > 15 cells HPF | 11 | 1 | 12 (12) | < .001 |
| CD4/8 pattern (F) | 29 | 40 | 69 (68) | .2 |
| CD25 pattern (F) | 31 | 7 | 38 (37) | < .001 |
| Transformation | 12 (32) | 9 (14) | 20 (20) | .04 |
BM indicates bone marrow; CR, complete remission; PR, partial remission; NR, no response; MD, median; IPI, International Prognostic Index; LAM, lymphoma-associated macrophages; HPF, high-power field; and F, follicular pattern.
*IPI group 1 versus 2/3.
†CR versus PR/NR.
‡Grade 1 versus 2/3.